[February 02, 2016]

Respiratory Syncytial Virus (RSV) Infections Pipeline Review, H2 2015 - Research and Markets

Research and Markets (http://www.researchandmarkets.com/research/tqltdv/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Respiratory Syncytial Virus (RSV) Infections Overview
3. Therapeutics Development
4. Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Overview
5. Pipeline Products for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis
6. Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies
7. Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes
8. Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies
13. Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes
14. Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development

• 3-V Biosciences, Inc.
• Ablynx NV
• ADMA Biologics, Inc.
• Agilvax, Inc.
• AmVac AG
• Aridis Pharmaceuticals LLC
• Bavarian Nordic A/S
• Biota Pharmaceuticals, Inc.
• Emergent BioSolutions Inc.
• Evec, Inc.
• F. Hoffmann-La Roche Ltd.
• Folia Biotech Inc.
• GenVec, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline Plc
• Globavir Biosciences, Inc.
• Humabs BioMed SA
• iBio, Inc.
• ILiAD Biotechnologies, LLC
• MedImmune, LLC
• Medivir AB
• Merck & Co., Inc.
• MSM Protein Technologies, Inc.
• Mucosis B.V.
• NanoBio Corporation
• Navigen Pharmaceuticals, Inc.
• Romark Laboratories, L.C.
• Sirnaomics, Inc.
• Spider Biotech
• Spring Bank Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• TechnoVax, Inc.
• The International Biotechnology Center (IBC) Generium
• Vaxart, Inc.
• VBI Vaccines Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160202005994/en/

[ Back To TMCnet.com's Homepage ]